We take on some of the toughest cancers with a single goal in mind: to help more patients around the world lead fuller, longer lives.
Building on expertise to tackle the toughest cancers
Our scientific research has led to critical discoveries in the treatment of blood cancer. Building upon our strong commitment to patients and existing leadership in blood cancers, we are now boldly expanding our footprint in solid tumors. Our robust portfolio in blood cancers and solid tumors is comprised of first-of-its kind treatments and an advancing pipeline of more than 20 investigational assets that are designed to tackle some of the most difficult-to-treat cancers in the world.
Research interests
We focus on creating targeted medicines that either impede the reproduction of cancer cells or enable their death. We achieve this through multiple modalities such as immuno-oncology approaches, tumor antigen targeting, and taking advantage of specific tumor dependencies. Our research interests include:
- Identifying and targeting mechanisms that allow tumor cells to proliferate and survive, including under-explored forms of regulated cell death, such as necroptosis and ferroptosis
- Investigating how to re-energize T cells so that they can retain their fitness and continue to destroy tumor cells
- Advancing the use of Antibody Drug Conjugates (ADCs) to target and deliver potent toxins and targeted agents to cancer cells
- Creating new technologies to improve the efficacy of bispecific biologics in treating both solid tumors and blood cancers, enabling the development of therapies with highly targeted potential
- Innovating in the field of targeted protein degradation by designing protein degraders that bind to a protein of interest and trigger its proteasomal degradation
- Developing CAR-T cell therapies that attack cancers with healthy donor immune cells engineered to target and kill tumor cells while being resistant to host immune system rejection
